title: [Metastatic Renal Cell Carcinoma in Paranasal Sinus for which Periodic Drug Withdrawal Schedule of Axitinib was Effective : A Case Report].
abstract: A 73-year-old male patient underwent a right nephrectomy for renal cell carcinoma in 2008, and interferon-alpha was initiated as adjuvant treatment. Computed tomography (CT) scans showed lymphadenopathy above the left diaphragm, and treatment with interferon-2 was subsequently initiated in 2009. Nasal bleeding manifested in February 2010, and CT scans showed a soft-tissue density mass mainly located in the ethmoid sinus. A biopsy of the lesion was performed, and metastatic renal cell carcinoma was diagnosed. Treatment with sorafenib was consequently initiated and the paranasal metastasis showed a temporary partial response (PR). However, the metastatic lesion increased in size and caused repeated nasal bleeding that required blood transfusion. Although treatment with everolims was initiated, adverse events, such as rush, hypertensionnemia, and anemia due to nasal bleeding, developed. Treatment with axitinib was subsequently initiated. However, because adverse events, such as severe diarrhea, renal dysfunction and proteinuria manifested, the dose of axitinib was gradually decreased, and a periodic drug withdrawal schedule (11 days on, 3 days off) was finally initiated, which controlled these adverse events. The metastatic lesions showed a PR for 31months following axitinib administration.
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Arai
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Ito
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Tachi
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Akio
authors.initials: A
authors.lastname: Koga
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shinchi
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Ayako
authors.initials: A
authors.lastname: Masunaga
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Makoto
authors.initials: M
authors.lastname: Isono
authors.affiliation: The Department of Urology, National Defense Medical College.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Asano
mesh_terms: D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009392:Nephrectomy; D009669:Nose Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib